Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment
Ovarian cancers are a complex and heterogenic group of malignancies that are difficult to detect, diagnose and treat. Fortunately, considerable knowledge of ovarian cancer specific biomarkers has been generated, that is pertinent to the development of novel theranostic platforms by combining therapi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Drug Delivery |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fddev.2024.1339936/full |
| _version_ | 1827159895074406400 |
|---|---|
| author | Weranga Rajapaksha Riya Khetan Ian R. D. Johnson Anton Blencowe Anton Blencowe Sanjay Garg Hugo Albrecht Todd A. Gillam Todd A. Gillam |
| author_facet | Weranga Rajapaksha Riya Khetan Ian R. D. Johnson Anton Blencowe Anton Blencowe Sanjay Garg Hugo Albrecht Todd A. Gillam Todd A. Gillam |
| author_sort | Weranga Rajapaksha |
| collection | DOAJ |
| description | Ovarian cancers are a complex and heterogenic group of malignancies that are difficult to detect, diagnose and treat. Fortunately, considerable knowledge of ovarian cancer specific biomarkers has been generated, that is pertinent to the development of novel theranostic platforms by combining therapies and diagnostics. Genomic and proteomic data has been invaluable in providing critical biomolecular targets for ovarian cancer theranostic approaches. Exploitation of the wealth of biomarker research that has been conducted offers viable targets as beacons for ovarian cancer detection, diagnosis, and therapeutic targeting. These markers can be used in theranostics, a treatment strategy that combines therapy and diagnostics and is common in nuclear medicine, where radionuclides are used for both diagnosis and treatment. The development of theranostics has taken substantial focus in recent years in the battle against ovarian cancer. Yet to date only one theranostic technology has emerged in clinical practice. However, given the wealth of ovarian cancer biomarkers the field is poised to see the emergence of revolutionary disease treatment and monitoring outcomes through their incorporation into the development of theranostic strategies. The future of ovarian cancer treatment is set to enable precise diagnosis, targeted treatment, and vigilant monitoring. This review aims to assess the status of ovarian cancer diagnostic tools and biomarkers in practice, clinical development, or pre-clinical development, highlighting newly emerging theranostic applications. |
| first_indexed | 2024-03-08T09:07:40Z |
| format | Article |
| id | doaj.art-b4513d829c8b43c4a35196f93caa174d |
| institution | Directory Open Access Journal |
| issn | 2674-0850 |
| language | English |
| last_indexed | 2025-03-21T00:04:23Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Drug Delivery |
| spelling | doaj.art-b4513d829c8b43c4a35196f93caa174d2024-08-03T11:08:04ZengFrontiers Media S.A.Frontiers in Drug Delivery2674-08502024-02-01410.3389/fddev.2024.13399361339936Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatmentWeranga Rajapaksha0Riya Khetan1Ian R. D. Johnson2Anton Blencowe3Anton Blencowe4Sanjay Garg5Hugo Albrecht6Todd A. Gillam7Todd A. Gillam8Centre for Pharmaceutical Innovation (CPI), Clinical and Health Sciences, University of South Australia, Adelaide, SA, AustraliaCentre for Pharmaceutical Innovation (CPI), Clinical and Health Sciences, University of South Australia, Adelaide, SA, AustraliaCentre for Pharmaceutical Innovation (CPI), Clinical and Health Sciences, University of South Australia, Adelaide, SA, AustraliaCentre for Pharmaceutical Innovation (CPI), Clinical and Health Sciences, University of South Australia, Adelaide, SA, AustraliaApplied Chemistry and Translational Biomaterials (ACTB) Group, Clinical and Health Sciences, University of South Australia, Adelaide, SA, AustraliaCentre for Pharmaceutical Innovation (CPI), Clinical and Health Sciences, University of South Australia, Adelaide, SA, AustraliaCentre for Pharmaceutical Innovation (CPI), Clinical and Health Sciences, University of South Australia, Adelaide, SA, AustraliaCentre for Pharmaceutical Innovation (CPI), Clinical and Health Sciences, University of South Australia, Adelaide, SA, AustraliaApplied Chemistry and Translational Biomaterials (ACTB) Group, Clinical and Health Sciences, University of South Australia, Adelaide, SA, AustraliaOvarian cancers are a complex and heterogenic group of malignancies that are difficult to detect, diagnose and treat. Fortunately, considerable knowledge of ovarian cancer specific biomarkers has been generated, that is pertinent to the development of novel theranostic platforms by combining therapies and diagnostics. Genomic and proteomic data has been invaluable in providing critical biomolecular targets for ovarian cancer theranostic approaches. Exploitation of the wealth of biomarker research that has been conducted offers viable targets as beacons for ovarian cancer detection, diagnosis, and therapeutic targeting. These markers can be used in theranostics, a treatment strategy that combines therapy and diagnostics and is common in nuclear medicine, where radionuclides are used for both diagnosis and treatment. The development of theranostics has taken substantial focus in recent years in the battle against ovarian cancer. Yet to date only one theranostic technology has emerged in clinical practice. However, given the wealth of ovarian cancer biomarkers the field is poised to see the emergence of revolutionary disease treatment and monitoring outcomes through their incorporation into the development of theranostic strategies. The future of ovarian cancer treatment is set to enable precise diagnosis, targeted treatment, and vigilant monitoring. This review aims to assess the status of ovarian cancer diagnostic tools and biomarkers in practice, clinical development, or pre-clinical development, highlighting newly emerging theranostic applications.https://www.frontiersin.org/articles/10.3389/fddev.2024.1339936/fullovarian cancertumorbiomarkerstherapeuticsdiagnosticstheranostics |
| spellingShingle | Weranga Rajapaksha Riya Khetan Ian R. D. Johnson Anton Blencowe Anton Blencowe Sanjay Garg Hugo Albrecht Todd A. Gillam Todd A. Gillam Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment Frontiers in Drug Delivery ovarian cancer tumor biomarkers therapeutics diagnostics theranostics |
| title | Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment |
| title_full | Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment |
| title_fullStr | Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment |
| title_full_unstemmed | Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment |
| title_short | Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment |
| title_sort | future theranostic strategies emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment |
| topic | ovarian cancer tumor biomarkers therapeutics diagnostics theranostics |
| url | https://www.frontiersin.org/articles/10.3389/fddev.2024.1339936/full |
| work_keys_str_mv | AT werangarajapaksha futuretheranosticstrategiesemergingovariancancerbiomarkerstobridgethegapbetweendiagnosisandtreatment AT riyakhetan futuretheranosticstrategiesemergingovariancancerbiomarkerstobridgethegapbetweendiagnosisandtreatment AT ianrdjohnson futuretheranosticstrategiesemergingovariancancerbiomarkerstobridgethegapbetweendiagnosisandtreatment AT antonblencowe futuretheranosticstrategiesemergingovariancancerbiomarkerstobridgethegapbetweendiagnosisandtreatment AT antonblencowe futuretheranosticstrategiesemergingovariancancerbiomarkerstobridgethegapbetweendiagnosisandtreatment AT sanjaygarg futuretheranosticstrategiesemergingovariancancerbiomarkerstobridgethegapbetweendiagnosisandtreatment AT hugoalbrecht futuretheranosticstrategiesemergingovariancancerbiomarkerstobridgethegapbetweendiagnosisandtreatment AT toddagillam futuretheranosticstrategiesemergingovariancancerbiomarkerstobridgethegapbetweendiagnosisandtreatment AT toddagillam futuretheranosticstrategiesemergingovariancancerbiomarkerstobridgethegapbetweendiagnosisandtreatment |